Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry.
Maria ChaparroAna GarreElena RicartMarisa IborraFrancisco MesoneroIsabel VeraSabino RiestraValle García-SánchezM Luisa De CastroAlbert Martín-CardonaXavier AldeguerMiguel MínguezManuel Barreiro de-AcostaMontserrat RiveroFernando MuñozMontserrat AndreuAna BargallóCarlos González-MuñozaJose L Pérez CalleMariana Fe García-SepulcreFernando BermejoJose Maria HuguetJosé Luis CabriadaAna GutiérrezMiriam MañosaAlbert VilloriaAna Y CarbajoRufo LorenteSantiago García-LópezMarta PiquerasEsther HinojosaClaudia ArajolBeatriz SiciliaAna Macho ConesaEmpar SainzPedro AlmelaJordina LlaóOscar RonceroPatricia CamoCarlos TaxoneraManuel Van DomselaarRamón PajaresJesús LegidoRosa MadrigalAlfredo J LucendoGuillermo AlcaínEugeni DomènechFrancisco Javier García-Alonsonull nullPublished in: Alimentary pharmacology & therapeutics (2019)
Over 60% of IBD patients respond to vedolizumab. Many patients discontinue treatment over time. CD and disease burden impair both short- and long-term response. Vedolizumab seems to be safe in clinical practice.